Therapy Detail

Therapy Name Aldesleukin
Therapy Description

Aldesleukin may induce T cell-mediated tumor regression by activating the IL-2 receptor to enhance lymphocyte mitogenesis; enhance lymphocyte cytotoxicity; induce lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induce expression of interferon-gamma (NCI Dictionary).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Aldesleukin Proleukin IL-2
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03126916 Phase III Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Cisplatin Cyclophosphamide Thiotepa Crizotinib Dexrazoxane Carboplatin Aldesleukin Topotecan Dinutuximab Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Recruiting
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Recruiting
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Recruiting
NCT01409174 Phase Ib/II Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma Terminated
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Recruiting
NCT01701674 Phase I Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Active, not recruiting
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Recruiting
NCT02118285 Phase I Aldesleukin Epacadostat Cyclophosphamide Fludarabine Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Completed
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT03190941 Phase I Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients Recruiting
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Recruiting
NCT01640301 Phase Ib/II Aldesleukin WT1 sensitized T cells Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Active, not recruiting
NCT01038778 Phase Ib/II Entinostat Aldesleukin Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Active, not recruiting
NCT00338377 Phase II Cyclophosphamide + Fludarabine Aldesleukin Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization Recruiting
NCT01593670 Phase II Decitabine Aldesleukin Vorinostat Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Terminated
NCT02620865 Phase Ib/II Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT02796352 Phase II Aldesleukin A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Terminated
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting
NCT03056599 Gemcitabine Interferon alpha-2b Doxorubicin Pembrolizumab Eribulin interferon gamma Ipilimumab Trabectedin Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Active, not recruiting
NCT01258855 Phase II Aldesleukin Aflibercept Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Completed
NCT02027935 Phase II Aldesleukin Cyclophosphamide Ipilimumab Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 Active, not recruiting